Baxter International Inc. (BIT:1BAX)
Italy
· Delayed Price · Currency is EUR 27.93
-0.19 (-0.68%)
At close: May 9, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Chronic Therapies | - |
Log In |
Log In |
Log In |
Log In |
| Chronic Therapies Growth | - |
Log In |
Log In |
Log In |
Log In |
| Kidney Care | - |
Log In |
Log In |
Log In |
Log In |
| Kidney Care Growth | - |
Log In |
Log In |
Log In |
Log In |
| Medication Delivery | - |
Log In |
Log In |
Log In |
Log In |
| Medication Delivery Growth | - |
Log In |
Log In |
Log In |
Log In |
| Clinical Nutrition | - |
Log In |
Log In |
Log In |
Log In |
| Clinical Nutrition Growth | - |
Log In |
Log In |
Log In |
Log In |
| Infusion Therapies | 4.13B |
Log In |
Log In |
Log In |
Log In |
| Infusion Therapies Growth | 2.89% |
Log In |
Log In |
Log In |
Log In |
| Advanced Surgery | 1.11B |
Log In |
Log In |
Log In |
Log In |
| Advanced Surgery Growth | 3.84% |
Log In |
Log In |
Log In |
Log In |
| Medical Products & Therapies | 5.24B |
Log In |
Log In |
Log In |
Log In |
| Medical Products & Therapies Growth | 3.09% |
Log In |
Log In |
Log In |
Log In |
| Pharmaceuticals | 2.41B |
Log In |
Log In |
Log In |
Log In |
| Pharmaceuticals Growth | 4.77% |
Log In |
Log In |
Log In |
Log In |
| Acute Therapies | - |
Log In |
Log In |
Log In |
Log In |
| Acute Therapies Growth | - |
Log In |
Log In |
Log In |
Log In |
| Patient Support Systems | - |
Log In |
Log In |
Log In |
Log In |
| Patient Support Systems Growth | - |
Log In |
Log In |
Log In |
Log In |
| Surgical Solutions | - |
Log In |
Log In |
Log In |
Log In |
| Surgical Solutions Growth | - |
Log In |
Log In |
Log In |
Log In |
| Care & Connectivity Solutions | 1.84B |
Log In |
Log In |
Log In |
Log In |
| Care & Connectivity Solutions Growth | 3.72% |
Log In |
Log In |
Log In |
Log In |
| Front Line Care | 1.15B |
Log In |
Log In |
Log In |
Log In |
| Front Line Care Growth | -2.30% |
Log In |
Log In |
Log In |
Log In |
| Healthcare Systems & Technologies | 2.99B |
Log In |
Log In |
Log In |
Log In |
| Healthcare Systems & Technologies Growth | 1.32% |
Log In |
Log In |
Log In |
Log In |
| Injectables and Anesthesia | 1.38B |
Log In |
Log In |
Log In |
Log In |
| Injectables and Anesthesia Growth | 0.73% |
Log In |
Log In |
Log In |
Log In |
| Drug Compounding | 1.03B |
Log In |
Log In |
Log In |
Log In |
| Drug Compounding Growth | 10.71% |
Log In |
Log In |
Log In |
Log In |
| Other Revenue (Post-Q2 2023 Reporting) | 129.00M |
Log In |
Log In |
Log In |
Log In |
| Other Revenue (Post-Q2 2023 Reporting) Growth | 76.71% |
Log In |
Log In |
Log In |
Log In |
| BioPharma Solutions | - |
Log In |
Log In |
Log In |
Log In |
| BioPharma Solutions Growth | - |
Log In |
Log In |
Log In |
Log In |
| Other Revenue (Pre-Q3 2023 Reporting) | - |
Log In |
Log In |
Log In |
Log In |
| Other Revenue (Pre-Q3 2023 Reporting) Growth | - |
Log In |
Log In |
Log In |
Log In |
EBIT by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Medical Products & Therapies Operating Income | 967.00M |
Log In |
Log In |
Log In |
Log In |
| Medical Products & Therapies Operating Income Growth | -3.49% |
Log In |
Log In |
Log In |
Log In |
| Healthcare Systems & Technologies Operating Income | 494.00M |
Log In |
Log In |
Log In |
Log In |
| Healthcare Systems & Technologies Operating Income Growth | 12.79% |
Log In |
Log In |
Log In |
Log In |
| Pharmaceuticals Operating Income | 298.00M |
Log In |
Log In |
Log In |
Log In |
| Pharmaceuticals Operating Income Growth | -23.98% |
Log In |
Log In |
Log In |
Log In |
| Kidney Care Operating Income | - |
Log In |
Log In |
Log In |
Log In |
| Other Operating Income | 23.00M |
Log In |
Log In |
Log In |
Log In |
| Other Operating Income Growth | 53.33% |
Log In |
Log In |
Log In |
Log In |
Other
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| United States Revenue | 6.30B |
Log In |
Log In |
Log In |
Log In |
| United States Revenue Growth | 3.79% |
Log In |
Log In |
Log In |
Log In |
| Emerging Markets Revenue | 1.84B |
Log In |
Log In |
Log In |
Log In |
| Emerging Markets Revenue Growth | -1.08% |
Log In |
Log In |
Log In |
Log In |
| Rest of World Revenue | 3.76B |
Log In |
Log In |
Log In |
Log In |
| Rest of World Revenue Growth | 4.36% |
Log In |
Log In |
Log In |
Log In |
| Americas Revenue | - |
Log In |
Log In |
Log In |
Log In |
| Americas Revenue Growth | - |
Log In |
Log In |
Log In |
Log In |
| EMEA Revenue | - |
Log In |
Log In |
Log In |
Log In |
| EMEA Revenue Growth | - |
Log In |
Log In |
Log In |
Log In |
| APAC Revenue | - |
Log In |
Log In |
Log In |
Log In |
| APAC Revenue Growth | - |
Log In |
Log In |
Log In |
Log In |
| Hillrom Revenue | - |
Log In |
Log In |
Log In |
Log In |
| Hillrom Revenue Growth | - |
Log In |
Log In |
Log In |
Log In |
| Americas Operating Income | - |
Log In |
Log In |
Log In |
Log In |
| Americas Operating Income Growth | - |
Log In |
Log In |
Log In |
Log In |
| EMEA Operating Income | - |
Log In |
Log In |
Log In |
Log In |
| EMEA Operating Income Growth | - |
Log In |
Log In |
Log In |
Log In |
| APAC Operating Income | - |
Log In |
Log In |
Log In |
Log In |
| APAC Operating Income Growth | - |
Log In |
Log In |
Log In |
Log In |
| Hillrom Operating Income | - |
Log In |
Log In |
Log In |
Log In |
| Hillrom Operating Income Growth | - |
Log In |
Log In |
Log In |
Log In |